Yutaka Honda

GlaxoSmithKline KK researches, develops, imports, manufactures and sells toiletry products. The company was founded on August 18, 1928 and is headquartered in Tokyo, Japan

Part of JCR Pharmaceuticals Co., Ltd., JCR International SA is a Swiss pharmaceutical company that manufactures pharmaceutical products. The company is based in Fribourg, Switzerland.

ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA.

Japan Vaccine Co., Ltd. develops and markets preventive vaccines. The joint venture company is based in Tokyo, Japan.

Future Brain KK is a Japanese company that engages in securities dealing and real estate management business. The company is based in Tokyo, Japan.

Luca Science, Inc. is a Japanese preclinical stage biopharmaceutical company that specializes in mitochondrial therapy to restore cellular bioenergetics in dysfunctional or damaged tissues and organs. Luca Science is based in Chuo-ku, JP, and was founded in December 2018 by Masashi Suganuma. The company uses its platform technology to manufacture, store, and deliver innovative mitochondrial drugs to research and develop therapeutics for unmet medical needs in a wide range of diseases for which there have been no effective treatments. The CEO is Rick C. Tsai.

Sanofi-Aventis Groupe SA operates as a holding company, with interest in the manufacture and distribution of pharmaceutical products. The company was founded on December 19, 1995 and is headquartered in Paris, France.

Nomura Securities Co., Ltd. (NSC) is a wholly-owned brokerage subsidiary of Nomura Holdings, Inc. (TSE: 8604; NYSE: NMR). Headquartered in Tokyo, the firm was founded in 1925. NSC places a strong emphasis on research, both fundamental and quantitative. In addition to stock and bond underwriting, their activities include IPO and M&A advisory, wealth management, separately managed accounts, fund wrap services, prime brokerage and structured equity finance. Their clients include institutions, hedge funds, private banks and private equity funds as well as corporate clients and retail investors.

4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom.

Part of Medipal Holdings Corp., Mediceo Corp. is a Japanese company that wholesales drugs and medical devices. The company is based in Tokyo, Japan and was founded in 2004.

Part of Medipal Holdings Corp., MEDIE Co., Ltd. is a Japanese company that provides medical information through the internet and develops and distributes computer software and medical equipment and tools. The company is based in Tokyo, Japan. MEDIE Co. was acquired by Medipal Holdings Corp. on June 01, 2013 for $8.05 million.

Part of Barclays PLC, Barclays Securities Japan Ltd. is a brokerage company based in Tokyo, Japan. Barclays Securities Japan provides brokerage services. The Japanese company was founded in 1987. Kentaro Kiso has been the CEO of the company since 2014.